Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer.
about
Weekly paclitaxel plus trastuzumab in metastatic breast cancer pretreated with anthracyclines--a phase II multipractice studyPhase 1 combination study of eribulin mesylate with trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 positive breast cancer.Trastuzumab in advanced breast cancer--a decade of experience in GermanyPhase II trial of weekly nab-paclitaxel and carboplatin treatment with or without trastuzumab as nonanthracycline neoadjuvant chemotherapy for locally advanced breast cancer.Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.Can maintenance trastuzumab be stopped in patients with HER2-positive metastatic breast cancer?Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition.A phase II study of ixabepilone and trastuzumab for metastatic HER2-positive breast cancer.Receptor-based targeting of therapeutics.Management of patients treated with pertuzumab in the Australian clinical practice setting.Aerosol delivery of liposomal formulated paclitaxel and vitamin E analog reduces murine mammary tumor burden and metastases.Comment on "combination treatment including targeted therapy for advanced hepatocellular carcinoma".Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients.Tau and PTEN status as predictive markers for response to trastuzumab and paclitaxel in patients with HER2-positive breast cancer.Pre-treatment hormonal receptor status and Ki67 index predict pathologic complete response to neoadjuvant trastuzumab/taxanes but not disease-free survival in HER2-positive breast cancer patients.
P2860
Q33401069-85E0F73E-B1B9-4118-B098-9D03A73AFF83Q34964991-89916B2F-AF1B-4CE8-B474-FECF7DEC896CQ34969710-4C4B3A65-B432-4629-B9D2-C2A1A9A8F6CCQ35185733-DCACAC41-DC4E-449C-8A26-F8B367303312Q35611851-6F8D8FD2-F8EE-49D3-8A3C-EAA86E098FD0Q35699689-9C78B461-E831-4C75-9431-88CB07B89B1AQ36729376-E8BB40D0-3329-4F2E-B7CB-DCEA239695EDQ36950497-030C9D5B-ECC3-4F9F-B010-613BDC8B1D9FQ38084739-29E378F4-FE2D-4E43-89FE-4DA46062A0B0Q38850594-B380960E-41DA-4511-8EC4-5FEBD64B2CF2Q39816322-A4567F14-74A7-4CB9-9628-800663BF0199Q41544681-CDA4C71C-018D-417E-8760-921D8BBF9221Q52578959-16337F02-340A-46EC-9F86-629990309FBEQ53600525-B3E72DC0-66AB-4520-B875-3C86D0938D8AQ54513997-541EA7AB-FDC9-4375-98E1-BD1873B4C8C4
P2860
Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical efficacy of taxane-tr ...... tive metastatic breast cancer.
@en
Clinical efficacy of taxane-tr ...... tive metastatic breast cancer.
@nl
type
label
Clinical efficacy of taxane-tr ...... tive metastatic breast cancer.
@en
Clinical efficacy of taxane-tr ...... tive metastatic breast cancer.
@nl
prefLabel
Clinical efficacy of taxane-tr ...... tive metastatic breast cancer.
@en
Clinical efficacy of taxane-tr ...... tive metastatic breast cancer.
@nl
P1433
P1476
Clinical efficacy of taxane-tr ...... tive metastatic breast cancer.
@en
P2093
Karen Bullock
Kimberly Blackwell
P304
P356
10.1634/THEONCOLOGIST.2007-0204
P577
2008-05-01T00:00:00Z